Recent studies have demonstrated that the beneficial metabolic effects of treatment with pioglitazone in PCOS patients partly occur through improvement of insulin sensitivity, including increased insulin-stimulated total, oxidative and non-oxidative glucose transport, and a decrease in insulin secretion [7], [8], similar to observations in patients with type 2 diabetes [9]. This evidence concerns the gene INS and polycystic ovary syndrome.